{"entity":{"id":"tricision-biotherapeutics","kind":"company","name":"Tricision Biotherapeutics","aka":["Beijing Tricision Biotherapeutics Inc","北京启辰生生物科技有限公司","Tricision"],"tldr":"Tricision is a Beijing company working on mRNA medicines and cancer vaccines. Its lead cancer product is a vaccine made from a patient's own immune cells loaded with survivin, a protein found in glioblastoma, given after diagnosis.","summary":"Beijing Tricision Biotherapeutics (Qichensheng) was founded in 2015, according to the company, and develops mRNA nucleic acid medicines, with mRNA, nanoparticle and cell delivery platforms and wholly owned subsidiaries in Zhuhai, Guangdong, and Yixing, Jiangsu; its pipeline covers mRNA cancer therapies and mRNA vaccines for infectious disease. Its lead cancer programme is a survivin-targeted dendritic cell injection for glioblastoma, and the company announced the start of a phase 2 trial. Its first registered cancer trial, NCT06524063, a phase 1 study of survivin-loaded dendritic cell injection in newly diagnosed glioblastoma, was posted on ClinicalTrials.gov in July 2024; a phase 2 study (NCT07715097) followed in July 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://tricisionbio.com/"},{"label":"ClinicalTrials.gov: phase 1 trial of survivin DC injection (NCT06524063)","url":"https://clinicaltrials.gov/study/NCT06524063"},{"label":"ClinicalTrials.gov: phase 2 trial of survivin DC injection (NCT07715097)","url":"https://clinicaltrials.gov/study/NCT07715097"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":["immunotherapy"],"technologies":["dendritic-cell-vaccines"],"targets":["birc5"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Facts are from the company's Chinese-language home page, read on 29 October 2026. Financing not stated; the home page mentions strategic agreements with Guoxin Health in 2024. Survivin is recorded under its gene name, BIRC5."],"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://tricisionbio.com/","founded":2015,"stage":"startup","investors":[],"funding":[]},"route":"/companies/tricision-biotherapeutics/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"dendritic-cell-vaccines","kind":"technology","name":"Dendritic cell vaccines","route":"/technologies/dendritic-cell-vaccines/"}],"target":[{"id":"birc5","kind":"target","name":"BIRC5","route":"/targets/birc5/"}]}}